EP 1423693 A4 20060607 - ERYTHROPOIETIN AND ANTI-TUMOR NECROSIS FACTOR ALPHA COMBINATION THERAPY
Title (en)
ERYTHROPOIETIN AND ANTI-TUMOR NECROSIS FACTOR ALPHA COMBINATION THERAPY
Title (de)
KOMBINATIONSTHERAPIE MIT ERYTHROPOETIN UND ANTI-TUMORNEKROSE-FAKTOR-ALPHA
Title (fr)
ERYTHROPOIETINE ET TRAITEMENT DE COMBINAISON ALPHA ANTI-FACTEUR DE NECROSE DES TUMEURS
Publication
Application
Priority
US 0124384 W 20010802
Abstract (en)
[origin: WO03012432A1] The present invention provides a method to treat anemic and non-anemic subjects having malignancies with a combination of EPO and an anti-Tumor Necrosis Factor compound such that there is a reduced need for transfusion and a greater hemoglobin level. The present invention provides a method to treat anemic and non-anemic subjects having malignancies with a combination of EPO and an anti-Tumor Necrosis Factor compound such that anemia may be successfully prevented or treated during the course of a chemotherapeutic regimen. The present invention provides a method to treat anemic and non-anemic subjects having malignancies with a combination of EPO and an anti-Tumor Necrosis Factor compound such that the patients show greater quality of life, show relief from fatigue symptoms, and show improvement in physical performance and well being.
IPC 8 full level
A61K 38/18 (2006.01); A61K 45/00 (2006.01); A01K 67/00 (2006.01); A01K 67/027 (2006.01); A01K 67/033 (2006.01); A01N 43/04 (2006.01); A61K 31/454 (2006.01); A61K 31/52 (2006.01); A61K 31/573 (2006.01); A61K 31/70 (2006.01); A61K 38/17 (2006.01); A61K 38/22 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 7/06 (2006.01); A61P 35/00 (2006.01); G01N 33/00 (2006.01)
CPC (source: EP)
A61K 31/454 (2013.01); A61K 31/52 (2013.01); A61K 31/70 (2013.01); A61K 38/1793 (2013.01); A61K 38/1816 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); A61P 7/06 (2017.12); A61P 35/00 (2017.12); C07K 2319/30 (2013.01)
Citation (search report)
- [E] WO 0236152 A1 20020510 - AMGEN INC [US]
- [E] WO 0210743 A1 20020207 - ORTHO MCNEIL PHARM INC [US]
- [Y] DEMETRI G D ET AL: "QUALITY-OF-LIFE BENEFIT IN CHEMOTHERAPY PATIENTS TREATED WITH EPOETIN ALFA IS INDEPENDENT OF DISEASE RESPONSE OR TUMOR TYPE: RESULTS FROM A PROSPECTIVE COMMUNITY ONCOLOGY STUDY", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 16, no. 10, October 1998 (1998-10-01), pages 3412 - 3425, XP009031711, ISSN: 0732-183X
- [Y] WOLCHOK J D ET AL: "PROPHYLACTIC RECOMBINANT EPOETIN ALFA MARKEDLY REDUCES THE NEED FOR BLOOD TRANSFUSION IN PATIENTS WITH METASTATIC MELANOMA TREATED WITH BIOCHEMOTHERAPY", CYTOKINES, CELLULAR AND MOLECULAR THERAPY, MARTIN DUNITZ PUBLISHERS, LONDON, GB, vol. 5, no. 4, December 1999 (1999-12-01), pages 205 - 206, XP009031732, ISSN: 1368-4736
- See references of WO 03012432A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 03012432 A1 20030213; CA 2456177 A1 20030213; EP 1423693 A1 20040602; EP 1423693 A4 20060607; JP 2004537569 A 20041216
DOCDB simple family (application)
US 0124384 W 20010802; CA 2456177 A 20010802; EP 01959479 A 20010802; JP 2003517575 A 20010802